Insight Molecular Diagnostics (IMDX) Investor presentation summary

Market opportunity and industry context

• Transplant monitoring represents a $2B clinical market in the US, characterized as underpenetrated and inefficient, with significant potential for disruption.

• Regulated transplant testing is identified as a $1B+ greenfield global opportunity.

• High clinical demand, strong reimbursement, and intellectual property protection support market positioning.

Business model and value proposition

• Molecular diagnostics empower clinicians to reduce uncertainty and improve patient outcomes, while enabling researchers to innovate.

• Intellectual property protection and high reimbursement rates may lead to high margins and profitability, with a capital-light model targeting software-like gross margins.

• Once adopted as standard of care, recurring revenue streams can last over 30 years per customer.

Strategic partnerships and commercialization

• Bio-Rad has become a top five shareholder through multiple equity investments and will help commercialize GraftAssure RUO, with exclusive rights outside the US.

• Coordinated rapid development of an IVD platform, with an exclusive negotiating period for Bio-Rad to acquire IVD commercial rights upon FDA clearance.